ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2636

Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Abstract Number: 2637

Chaperone-mediated Autophagy in Synovitis Distinguishes Psoriatic Arthritis from Rheumatoid Arthritis
Abstract Number: 2638

Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level
Abstract Number: 2639

Exploring Weight Trends in Psoriatic Arthritis: Unraveling Effects of Drugs
Abstract Number: 2640

Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Abstract Number: 2641

Identification of Systemic Sclerosis Intrinsic Subtypes in the ASSET Clinical Trial Using PBC Gene Expression
Abstract Number: 2642

Identifying Systemic Sclerosis Molecular Subtypes by Their Cellular Signature – Deconvoluting the Puzzle
Abstract Number: 2643

Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis
Abstract Number: 2644

Baseline Fibroblast Immunophenotype Predicts Clinical Improvement Among Individuals with Early Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2645

Human NCF1-p.R90H Variant Promotes Pulmonary Fibrosis in the Bleomycin-induced Mouse Model and Systemic Sclerosis Patients via Expansion of SPP1+Monocytes-derived Macrophages
Abstract Number: 2646

Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries
Abstract Number: 2647

Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a DADA2 Cohort of 101 Patients
Abstract Number: 2648

Diagnosis of Giant Cell Arteritis by 18F-FDG PET/CT in Patients on Glucocorticoid Therapy: Importance of Delayed Imaging
Abstract Number: 2649

Defining Clinical Subgroups of Patients with Relapsing Polychondritis: A Latent Class and Decision Tree Analysis in Two Independent Prospective Cohorts
Abstract Number: 2650

Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Complications in Giant Cell Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].